Luke J Jacobi - Spark Newswire

1 minute read

Galmed Pharmaceuticals Q4 EPS $(0.30), Inline

Today, 5:50 PM

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.30) per share which met the analyst consensus estimate. This is a 37.5 percent increase over losses of $(0.48) per share from the same period last year.

GLMD

1 minute read

RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis

By Luke J Jacobi

Today, 5:50 PM

RAPT Therapeutics, Inc. (NASDAQ: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmetRAPT Therapeutics, Inc.

RAPT

1 minute read

GoldMining Inc Acquires an Existing 1% Net Smelter Return Royalty on the Company’s Yarumalito Project in Columbia

By Luke J Jacobi

Today, 5:50 PM

Pursuant to the agreement, the Company paid Newrange CAD$100,000 in cash and delivered 10,000 common shares of the Company.Pursuant to the agreement, the Company paid Newrange CAD$100,000 in cash and delivered 10,000 common shares of the Company.

GLDG

1 minute read

News

C4 Therapeutics Announces 2022 Targets

By Luke J Jacobi

Today, 5:50 PM

– Initial Phase 1 Data for CFT7455, a Novel IKZF1/3 Degrader, Expected in 1H 2022– – IND Clearance Achieved for CFT8634, a Degrader Targeting BRD9; On Track to Initiate Phase 1 Trial in Synovial

CCCC

1 minute read

SI-BONE Raises FY2021 Sales Guidance $89.00M-90.00M vs 89.4M Est

By Luke J Jacobi

Today, 5:50 PM

SI-BONE (NASDAQ:SIBN) raises FY2021 sales outlook from $89.00 million-90.00 million to $89.80 million-90.10 million.

SIBN

1 minute read

FDA
News

Applied Therapeutics to Hold on Submitting a New Drug Application for its AT-007 for Treatment of Galactosemia Pending Additional Discussions with the FDA

By Luke J Jacobi

Today, 5:50 PM

The ongoing ACTION-Galactosemia Kids Phase 3 study is evaluating the impact of AT-007 treatment vs. placebo on clinical outcomes over time, including cognition, speech, behavior and motor skills. Clinical outcomes are

APLT

1 minute read

Infobird To Acquire a 51% Stake in Shanghai Qishuo Network Technology, Terms Not Disclosed

By Luke J Jacobi

Today, 5:50 PM

With several years of development, Qishuo has gained deep insights into retail stores' operations, especially in the clothing and footwear industry. The customer base of Qishuo comprises several leading

IFBD

1 minute read

News

TRACON Pharma’s Independent Data Monitoring Committee Recommends the Company Continue its ENVASARC Trial

By Luke J Jacobi

Today, 5:50 PM

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics today announced the Independent Data Monitoring

TCON

1 minute read

FactSet to Acquire CUSIP Global Services for $1.925 Billion

By Luke J Jacobi

Today, 5:50 PM

CGS generates annual revenues of approximately $175 million with consistent revenue growth rates in the mid- to high-single digit range. It is expected to deliver robust margins and be immediately accretive to

FDS

1 minute read

SPAC Dynamics Special Purpose to Acquire Senti Bio, A Gene Circuit-Engineered Cell Company

By Luke J Jacobi

Today, 5:50 PM

- Business combination with Dynamics Special Purpose Corp. (NASDAQ:DYNS) is expected to provide more than $296 million in gross proceeds, over $153 million of which is fully committed in a common

DYNS